Sintilimab plus Lenvatinib after liver cancer surgery for PVTT
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether a combination of two drugs (sintilimab and lenvatinib) given after surgery can help prevent liver cancer from coming back in people who had a tumor growing into the portal vein (a major blood vessel in the liver). You may join if you recently had successful surgery and haven't had other treatments yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cancer (HCC) and had surgery to remove it completely.
- Your cancer was found to have spread into the portal vein (the main blood vessel of the liver).
- You are between 18 and 75 years old.
- You have not had any prior chemotherapy, targeted therapy, or other cancer treatments for your liver cancer.
- You have good liver function (Child-Pugh score A or B7) and good overall health (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the immunotherapy drug Sintilimab, given after surgery, can help prevent liver cancer from coming back in people whose tumors had tiny blood vessel invasion. It is for patients who have fully recovered from surgery and have not had other cancer treatments before.
This trial tests a combination of immunotherapy (sintilimab), a targeted anti-angiogenic drug (bevacizumab biosimilar), and liver-directed therapies (TACE-HAIC) before and after surgery for hepatocellular carcinoma that has spread to the portal vein. The goal is to see if this approach improves outcomes for patients with advanced but resectable liver cancer.
This trial combines a procedure called TIPS (which helps relieve pressure in the liver) with two drugs—lenvatinib (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—for people with advanced liver cancer that has spread into the main vein of the liver. It aims to see if this combination can help control the cancer and improve symptoms.
This trial studies whether combining two medicines (tislelizumab and sitravatinib) given after curative liver cancer surgery can help prevent the cancer from coming back. It is for people with liver cancer at high risk of recurrence, who have fully recovered from surgery and have no spread beyond the liver.
This trial tests a combination of two drugs (lenvatinib and sintilimab) plus a procedure called SIRT (radioactive beads) for people with liver cancer that can't be surgically removed. The goal is to see if this triple approach works better than standard treatments.
This trial tests a combination of treatments for liver cancer that has spread to the main portal vein. It uses a special stent, radiation seeds, and targeted therapies to shrink the tumor and improve blood flow. This may help patients who haven't had certain prior treatments.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.